Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6191266 | European Journal of Surgical Oncology (EJSO) | 2016 | 20 Pages |
Abstract
Results of contemporary adjuvant clinical trials will not be comparable as inclusion criteria differ significantly. Risk assessment according to our model might improve patient selection in clinical trials by defining a high-risk group (28% of all patients) with a 5-year-recurrence rate of almost 40%.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
I. Wolff, M. May, B. Hoschke, R. Zigeuner, L. Cindolo, G. Hutterer, L. Schips, O. De Cobelli, B. Rocco, C. De Nunzio, A. Tubaro, I. Coman, B. Feciche, M. Truss, O. Dalpiaz, R.S. Figenshau, K. Madison, M. Sánchez-Chapado, S. Brookman-May,